Top

Published in:

Open Access 01-06-2022 | Obesity

Interplay of Obesity, Ethanol, and Contaminant Mixture on Clinical Profiles of Cardiovascular and Metabolic Diseases: Evidence from an Animal Study

Authors: Maria Florian, Bai Li, Dominique Patry, Jocelyn Truong, Don Caldwell, Melanie C. Coughlan, Robert Woodworth, Jin Yan, Qixuan Chen, Ivan Petrov, Laziyan Mahemuti, Michelle Lalande, Nanqin Li, Laurie H. M. Chan, William G. Willmore, Xiaolei Jin

Published in: Cardiovascular Toxicology | Issue 6/2022

Abstract

Obesity, ethanol, and contaminants are known risk factors of cardiovascular and metabolic diseases (CMD). However, their interplay on clinical profiles of these diseases remains unclear, and thus were investigated in this study. Male lean or obese JCR rats were given water or 10% ethanol and orally treated with or without a contaminant mixture (CM) dissolved in corn oil and loaded on two cookies at 0, 1.6, or 16 mg/kg BW/day dose levels for 4 weeks. The CM consisted 22 environmental contaminants found in human blood or serum of Northern populations. Over 60 parameters related to CMD were examined. The results revealed that obesity in JCR rats resembles the clinical profiles of non-alcoholic fatty liver disease in humans. Obesity was also associated with increased serum and organ retention of mercury, one of the chemical components of CM. Exposure to ethanol lightened hyperlipidemia, increased liver retention of mercury, and increased risk for hypertension in the obese rats. CM lessened hyperlipidemia and hyperenzymemia, worsened systemic inflammation and increased the risk for hypertension in the obese rats. CM markedly increased serum ethanol levels with or without ethanol exposure. Tissue total mercury contents significantly correlated with clinical parameters with altered profiles by both ethanol and obesity. These results suggest that obese individuals may be more prone to contaminant accumulation. Ethanol and CM exposure can alter clinical profiles associated with obesity, which may lead to misdiagnosis of CMD associated with obesity. CM can alter endogenous production and/or metabolism of ethanol, further complicating disease progression, diagnosis, and treatment.

Available only for authorised users

Thomas, M. R., & Lip, G. Y. (2017). Novel risk markers and risk assessments for cardiovascular disease. Circulation Research, 120(1), 133–149. https://doi.org/10.1161/CIRCRESAHA.116.309955CrossRefPubMed

Stegemann, C., Pechlaner, R., Willeit, P., Langley, S. R., Mangino, M., Mayr, U., Menni, C., Moayyeri, A., Santer, P., Rungger, G., Spector, T. D., Willeit, J., Kiechl, S., & Mayr, M. (2014). Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation, 129(18), 1821–1831. https://doi.org/10.1161/CIRCULATIONAHA.113.002500CrossRefPubMed

Shapiro, M. D., & Fazio, S. (2016). From lipids to inflammation: New approaches to reducing atherosclerotic risk. Circulation Research, 118(4), 732–749. https://doi.org/10.1161/CIRCRESAHA.115.306471CrossRefPubMed

Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017). Inflammatory processes in cardiovascular disease: A route to targeted therapies. Nature Review of Cardiology., 14(3), 133–144. https://doi.org/10.1038/nrcardio.2016.185CrossRef

Moriya, J. (2019). Critical roles of inflammation in atherosclerosis. Journal of Cardiology., 73(1), 22–27. https://doi.org/10.1016/j.jjcc.2018.05.010CrossRefPubMed

Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Jr., Grover, S., Gupta, M., Hegele, R. A., Lau, D. C., Leiter, L. A., Lonn, E., Mancini, G. B., McPherson, R., Ngui, D., Poirier, P., Sievenpiper, J. L., … Ward, R. (2016). Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can Journal of Cardiology., 32(11), 1263–1282. https://doi.org/10.1016/j.cjca.2016.07.510CrossRef

Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G., Hamburg, N. M., Kinlay, S., Lookstein, R., Misra, S., Mureebe, L., Olin, J. W., Patel, R. A., Regensteiner, J. G., Schanzer, A., Shishehbor, M. H., Stewart, K. J., … Walsh, M. E. (2017). 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: Executive summary: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation, 135(12), e686–e725. https://doi.org/10.1161/CIR.0000000000000470CrossRefPubMed

Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk [published correction appears in Atherosclerosis. 292:160–162] published correction appears in Atherosclerosis. 294:80–82. Atherosclerosis (2019). 290, 140–205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014.

van Holten, T. C., Waanders, L. F., de Groot, P. G., Vissers, J., Hoefer, I. E., Pasterkamp, G., Prins, M. W., & Roest, M. (2013). Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS ONE, 8(4), e62080. https://doi.org/10.1371/journal.pone.0062080CrossRefPubMedPubMedCentral

10.

Montgomery, J. E., & Brown, J. R. (2013). Metabolic biomarkers for predicting cardiovascular disease. Vascular Health Risk Management., 9, 37–45. https://doi.org/10.2147/VHRM.S30378CrossRefPubMedPubMedCentral

11.

Afari, M. E., & Bhat, T. (2016). Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: An update. Expert Review of Cardiovascular Therapy, 14(5), 573–577. https://doi.org/10.1586/14779072.2016.1154788CrossRefPubMed

12.

Woodward, L., Akoumianakis, I., & Antoniades, C. (2017). Unravelling the adiponectin paradox: Novel roles of adiponectin in the regulation of cardiovascular disease. British Journal of Pharmacology., 174(22), 4007–4020. https://doi.org/10.1111/bph.13619CrossRefPubMed

13.

Mandviwala, T., Khalid, U., & Deswal, A. (2016). Obesity and cardiovascular disease: A risk factor or a risk marker? Current Atherosclerosis Reports, 18(5), 21. https://doi.org/10.1007/s11883-016-0575-4CrossRefPubMed

14.

Vecchié, A., Dallegri, F., Carbone, F., Bonaventura, A., Liberale, L., Portincasa, P., Frühbeck, G., & Montecucco, F. (2018). Obesity phenotypes and their paradoxical association with cardiovascular diseases. European Journal of Internal Medicine, 48, 6–17. https://doi.org/10.1016/j.ejim.2017.10.020CrossRefPubMed

15.

Buckley, A. J., Thomas, E. L., Lessan, N., Trovato, F. M., Trovato, G. M., & Taylor-Robinson, S. D. (2018). Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. Diabetes Research Clinical Practice, 144, 144–152. https://doi.org/10.1016/j.diabres.2018.08.011CrossRefPubMed

16.

Tana, C., Ballestri, S., Ricci, F., Di Vincenzo, A., Ticinesi, A., Gallina, S., Giamberardino, M. A., Cipollone, F., Sutton, R., Vettor, R., Fedorowski, A., & Meschi, T. (2019). Cardiovascular risk in non-alcoholic fatty liver disease: Mechanisms and therapeutic implications. International Journal of Environmental Research and Public Health, 16(17), 3104. https://doi.org/10.3390/ijerph16173104CrossRefPubMedCentral

17.

O’Keefe, J. H., Bybee, K. A., & Lavie, C. J. (2007). Alcohol and cardiovascular health: The razor-sharp double-edged sword. Journal of American Collage of Cardiology., 50, 1009–1014. https://doi.org/10.1016/j.jacc.2007.04.089CrossRef

18.

O’Keefe, E. L., DiNicolantonio, J. J., O’Keefe, J. H., & Lavie, C. J. (2018). Alcohol and CV health: Jekyll and Hyde J-curves. Progress in Cardiovascular Diseases, 61(1), 68–75. https://doi.org/10.1016/j.pcad.2018.02.001CrossRefPubMed

19.

Manolis, T. A., Manolis, A. A., & Manolis, A. S. (2019). Cardiovascular effects of alcohol: A double-edged sword/how to remain at the nadir point of the J-curve? Alcohol, 76, 117–129. https://doi.org/10.1016/j.alcohol.2018.08.011CrossRefPubMed

20.

Barr, T., Helms, C., Grant, K., & Messaoudi, I. (2016). Opposing effects of alcohol on the immune system. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 65, 242–251. https://doi.org/10.1016/j.pnpbp.2015.09.001CrossRefPubMed

21.

Rapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A. D., Denaxas, S., White, I. R., Caulfield, M. J., Deanfield, J. E., Smeeth, L., Williams, B., Hingorani, A., & Hemingway, H. (2014). Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. The Lancet, 383, 1899–1911. https://doi.org/10.1016/S0140-6736(14)60685-1CrossRef

22.

Min, J. Y., Cho, J. S., Lee, K. J., Park, J. B., Park, S. G., Kim, J. Y., & Min, K. B. (2011). Potential role for organochlorine pesticides in the prevalence of peripheral arterial diseases in obese persons: Results from the national health and nutrition examination survey 1999–2004. Atherosclerosis, 218(1), 200–206. https://doi.org/10.1016/j.atherosclerosis.2011.04.044CrossRefPubMed

23.

Aminov, Z., Haase, R., Rej, R., Schymura, M. J., Santiago-Rivera, A., Morse, G., & Environment, A. T. F. (2016). Diabetes prevalence in relation to serum concentrations of polychlorinated biphenyl (PCB) congener groups and three chlorinated pesticides in a Native American population. Environmental Health Perspectives, 124(9), 1376–1383. https://doi.org/10.1289/ehp.1509902CrossRefPubMedPubMedCentral

24.

Perkins, J. T., Petriello, M. C., Newsome, B. J., & Hennig, B. (2016). Polychlorinated biphenyls and links to cardiovascular disease. Environmental Sciences and Polluttion Research International, 23(3), 2160–2172. https://doi.org/10.1007/s11356-015-4479-6CrossRef

25.

Hu, X. F., Singh, K., & Chan, H. M. (2018). Mercury exposure, blood pressure, and hypertension: A systematic review and dose–response meta-analysis. Environmental Health Perspectives, 126(07), 076002. https://doi.org/10.1289/EHP2863CrossRefPubMedPubMedCentral

26.

Le Magueresse-Battistoni, B., Vidal, H., & Naville, D. (2018). Environmental pollutants and metabolic disorders: The multi-exposure scenario of life. Frontier in Endocrinology (Lausanne), 9, 582. https://doi.org/10.3389/fendo.2018.00582CrossRef

27.

Baker, J. R. E. L., Landrigan, P. J., Glueck, C. J., Zack, J. R. M. M., Liddl, J. A., Burse, V. W., & Needham, L. L. (1980). Metabolic consequences of exposure to polychlorinated biphenyls (PCB) in sewage sludge. American Journal of Epidemiology., 112(4), 553–563. https://doi.org/10.1093/oxfordjournals.aje.a113024CrossRefPubMed

28.

Goncharov, A., Haase, R. F., Santiago-Rivera, A., Morse, G., McCaffrey, R. J., Rej, R., & Environment, A. T. F. (2008). High serum PCBs are associated with elevation of serum lipids and cardiovascular disease in a Native American population. Environmental Research, 106(2), 226–239. https://doi.org/10.1016/j.envres.2007.10.006CrossRefPubMed

29.

Kreiss, K., Zack, M. M., Kimbrough, R. D., Needham, L. L., Smrek, A. L., & Jones, B. T. (1981). Association of blood pressure and polychlorinated biphenyl levels. Journal of the American Medical Association, 245(24), 2505–2509. https://doi.org/10.1001/jama.1981.03310490023017CrossRefPubMed

30.

Raffetti, E., Donato, F., Speziani, F., Scarcella, C., Gaia, A., & Magoni, M. (2018). Polychlorinated biphenyls (PCBs) exposure and cardiovascular, endocrine and metabolic diseases: A population-based cohort study in a North Italian highly polluted area. Environmental International, 120, 215–222. https://doi.org/10.1016/j.envint.2018.08.022CrossRef

31.

Sergeev, A. V., & Carpenter, D. O. (2005). Hospitalization rates for coronary heart disease in relation to residence near areas contaminated with persistent organic pollutants and other pollutants. Environmental Health Perspectives, 113(6), 756–761. https://doi.org/10.1289/ehp.7595CrossRefPubMedPubMedCentral

32.

Sørensen, N., Murata, K., Budtz-Jørgensen, E., Weihe, P., & Grandjean, P. (1999). Prenatal methylmercury exposure as a cardiovascular risk factor at seven years of age. Epidemiology, 10(4), 370–375.CrossRef

33.

Fillion, M., Mergler, D., Passos, C. J. S., Larribe, F., Lemire, M., & Guimarães, J. R. D. (2006). A preliminary study of mercury exposure and blood pressure in the Brazilian Amazon. Environmental Health, 5(1), 29. https://doi.org/10.1186/1476-069X-5-29CrossRefPubMedPubMedCentral

34.

Stern, A. H. (2005). A review of the studies of the cardiovascular health effects of methylmercury with consideration of their suitability for risk assessment. Environmental Research, 98(1), 133–142. https://doi.org/10.1016/j.envres.2004.07.016CrossRefPubMed

35.

Valera, B., Dewailly, E., & Poirier, P. (2008). Cardiac autonomic activity and blood pressure among Nunavik Inuit adults exposed to environmental mercury: A cross-sectional study. Environmental Health, 7(1), 29. https://doi.org/10.1186/1476-069X-7-29CrossRefPubMedPubMedCentral

36.

Jin, X., Hidiroglou, N., Lok, E., Taylor, M., Kapal, K., Ross, N., Sarafin, K., Lau, A., De Souza, A., Chan, H. M., & Mehta, R. (2012). Dietary selenium (Se) and vitamin E (V(E)) supplementation modulated methylmercury-mediated changes in markers of cardiovascular diseases in rats. Cardiovascular Toxicology, 12(1), 10–24. https://doi.org/10.1007/s12012-011-9134-yCrossRefPubMed

37.

Hu, X. F., Singh, K., Kenny, T. A., & Chan, H. M. (2019). Prevalence of heart attack and stroke and associated risk factors among Inuit in Canada: A comparison with the general Canadian population. International Journal of Hygiene and Environmental Health, 222(2), 319–326. https://doi.org/10.1016/j.ijheh.2018.12.003CrossRefPubMed

38.

Johnson, J. A., Vermeulen, S. U., Toth, E. L., Hemmelgarn, B. R., Ralph-Campbel, K., Hugel, G., & Crowshoe, L. (2009). Increasing incidence and prevalence of diabetes among the status aboriginal population in urban and rural Alberta, 1995–2006. Canadian Journal of Public Health, 100(3), 231–236. https://doi.org/10.1007/BF03405547CrossRefPubMedPubMedCentral

39.

Ralph-Campbell, K., Oster, R. T., Connor, T., Pick, M., Pohar, S., Thompson, P., & Cardinal-Lamouche, S. (2009). Increasing rates of diabetes and cardiovascular risk in Métis settlements in northern Alberta. International Journal of Circumpolar Health, 68(5), 433–442. https://doi.org/10.3402/ijch.v68i5.17382CrossRefPubMed

40.

Rehm, J., & Roerecke, M. (2017). Cardiovascular effects of alcohol consumption. Trends in Cardiovascular Medicine, 27(8), 534–538. https://doi.org/10.1016/j.tcm.2017.06.002CrossRefPubMed

41.

Shield, K. D., Parry, C., & Rehm, J. (2013). Chronic diseases and conditions related to alcohol use. Alcohol Research, 35(2), 155–173.PubMed

42.

Willows, N., Johnson-Down, L., Kenny, T. A., Chan, H. M., & Batal, M. (2019). Modelling optimal diets for quality and cost: Examples from Inuit and First Nations communities in Canada. Applied Physiology, Nutrition, and Metabolism, 44(7), 696–703. https://doi.org/10.1139/apnm-2018-0624CrossRefPubMed

43.

Mailloux, R. J., Florian, M., Chen, Q., Yan, J., Petrov, I., Coughlan, M. C., Laziyan, M., Caldwell, D., Lalande, M., Patry, D., Gagnon, C., Sarafin, K., Truong, J., Chan, H. M., Ratnayake, N., Li, N., Willmore, W. G., & Jin, X. (2014). Exposure to a northern contaminant mixture (NCM) alters hepatic energy and lipid metabolism exacerbating hepatic steatosis in obese JCR rats. PLoS ONE, 9(9), e106832. https://doi.org/10.1371/journal.pone.0106832CrossRefPubMedPubMedCentral

44.

Mailloux, R., Fu, A., Florian, M., Petrov, I., Chen, Q., Coughlan, M. C., Laziyan, M., Yan, J., Caldwell, D., Patry, D., Lalande, M., Wang, G. S., Willmore, W., & Jin, X. (2015). A Northern contaminant mixture impairs pancreas function in obese and lean JCR rats and inhibits insulin secretion in MIN6 cells. Toxicology, 334, 81–93. https://doi.org/10.1016/j.tox.2015.06.001CrossRefPubMed

45.

Russell, J. C., Graham, S. E., & Richardson, M. (1998). Cardiovascular disease in the JCR:LA-cp rat. Molecular and Cellular Biochemistry, 188(1–2), 113–126.CrossRef

46.

Dewailly, E., Ayotte, P., Pereg, D., & Dery, S. (2006) Exposure to heavy metals and persistent organic pollutants in Nunavik: The Nunavik health study (human health). Synopsis of Research, 2005–2006 Northern Contaminants Program, 44–64.

47.

Michaud, K., Basso, C., d’Amati, G., Michaud, K., Basso, C., d’Amati, G., Giordano, C., Kholová, I., Preston, S. D., Rizzo, S., Sabatasso, S., Sheppard, M. N., Vink, A., van der Wal, A. C., Association for European Cardiovascular Pathology. (2020). Diagnosis of myocardial infarction at autopsy: AECVP reappraisal in the light of the current clinical classification. Virchows Archiv, 476, 179–194. https://doi.org/10.1007/s00428-019-02662-1CrossRefPubMed

48.

Shabana, S. S. U., & Sarwar, S. (2020). The abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects. Lipids in Health and Diseases., 19(1), 73. https://doi.org/10.1186/s12944-020-01248-0CrossRef

49.

Gany, A., & Aljaffar, Y. (2018). A study of serum lipid profile among obese and non-obese individuals: A hospital-based study from Karbala, Iraq. International Journal of Contemporary Medicine Research, 5(4), D17–D20. https://doi.org/10.21276/ijcmr.2018.5.4.11CrossRef

50.

Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice, 105(2), 141–150. https://doi.org/10.1016/j.diabres.2014.04.006CrossRefPubMed

51.

Unamuno, X., Gómez-Ambrosi, J., Rodríguez, A., Becerril, S., Frühbeck, G., & Catalán, V. (2018). Adipokine dysregulation and adipose tissue inflammation in human obesity. European Journal Clinical Investigation, 48(9), e12997. https://doi.org/10.1111/eci.12997CrossRef

52.

Hanley, A. J., Retnakaran, R., Qi, Y., Gerstein, H. C., Perkins, B., Raboud, J., Harris, S. B., & Zinman, B. (2009). Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. Journal of Clinical Endocrinology and Metabolism, 94(10), 3824–3832. https://doi.org/10.1210/jc.2009-0719CrossRefPubMed

53.

Vuong, J., Qiu, Y., La, M., Clarke, G., Swinkels, D. W., & Cembrowski, G. (2014). Reference intervals of complete blood count constituents are highly correlated to waist circumference: Should obese patients have their own “normal values?” American Journal of Hematology, 89(7), 671–677. https://doi.org/10.1002/ajh.23713CrossRefPubMed

54.

Gebrie, A., Gnanasekaran, N., Menon, M., Sisay, M., & Zegeye, A. (2018). Evaluation of lipid profiles and hematological parameters in hypertensive patients: Laboratory-based cross-sectional study. SAGE Open Medicine, 6, 2050312118756663. https://doi.org/10.1177/2050312118756663CrossRefPubMedPubMedCentral

55.

Singh, S., Dwivedi, A., & Mittal, P. C. (2018). Anisocytosis is associated with high body mass index and poor adaptation to oxidative stress in obese patients with type 2 diabetes mellitus. Journal of Life Sciences, 10(2), 123–131. https://doi.org/10.31901/24566306.2018/10.02.232CrossRef

56.

Thongprayoon, C., Cheungpasitporn, W., & Kashani, K. (2016). Serum creatinine level, a surrogate of muscle mass, predicts mortality in critically ill patients. Journal of Thoracic Diseases, 8(5), E305-311. https://doi.org/10.21037/jtd.2016.03.62CrossRef

57.

Schutte, J. E., Longhurst, J. C., Gaffney, F. A., Bastian, C., & Blomqvist, C. G. (1981). Total plasma creatinine: An accurate measure of total striated muscle mass. Journal of Applied Physiology Respirational, Environmental, and Exercise Physiology, 51, 762–766. https://doi.org/10.1152/jappl.1981.51.3.762CrossRef

58.

Park, J., Mehrotra, R., Rhee, C. M., et al. (2013). Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients. Nephrology Dialysis and Transplantation, 28, 2146–2155. https://doi.org/10.1093/ndt/gft213CrossRef

59.

Chaudhari, U., Newcomb, J., & Hansen, B. (2018). Serum creatinine progressively decreases with obesity and type 2 diabetes in nonhuman primates. Diabetes. https://doi.org/10.2337/db18-1931-PCrossRef

60.

Cuthbert, J. J., Pellicori, P., Rigby, A., Pan, D., Kazmi, S., Shah, P., & Clark, A. L. (2018). Low serum chloride in patients with chronic heart failure: Clinical associations and prognostic significance. European Journal of Heart Failure, 20(10), 1426–1435. https://doi.org/10.1002/ejhf.1247CrossRefPubMed

61.

De Bacquer, D., De Backer, G., De Buyzere, M., & Kornitzer, M. (1998). Is low serum chloride level a risk factor for cardiovascular mortality? Journal of Cardiovascular Risk, 5(3), 177–184. https://doi.org/10.1177/174182679800500307CrossRefPubMed

62.

Pfortmueller, C. A., Uehlinger, D., von Haehling, S., & Schefold, J. C. (2018). Serum chloride levels in critical illness-the hidden story. Intensive Care Medicine Experimental, 6(1), 10. https://doi.org/10.1186/s40635-018-0174-5CrossRefPubMedPubMedCentral

63.

McCallum, L., Lip, S., & Padmanabhan, S. (2015). The hidden hand of chloride in hypertension. Pflügers Archiv - European Journal of Physiology, 467, 595–603. https://doi.org/10.1007/s00424-015-1690-8CrossRefPubMedPubMedCentral

64.

Piani, F., Cicero, A. F. G., & Borghi, C. (2021). Uric acid and hypertension: Prognostic role and guide for treatment. Journal Clinical Medicine, 10(3), 448. https://doi.org/10.3390/jcm10030448CrossRef

65.

Feig, D. I., Kang, D. H., & Johnson, R. J. (2008). Uric acid and cardiovascular risk. The New England Journal of Medicine, 359, 1811–1821. https://doi.org/10.1056/NEJMra0800885CrossRefPubMedPubMedCentral

66.

Cicero, A. F. G., Fogacci, F., Giovannini, M., Grandi, E., D’Addato, S., Borghi, C., Brisighella Heart Study Group. (2019). Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension. Journal of Hypertension, 37(4), 728–731. https://doi.org/10.1097/HJH.0000000000001927CrossRefPubMed

67.

Giles, T. D., Sander, G. E., Nossaman, B. D., & Kadowitz, P. J. (2012). Impaired vasodilation in the pathogenesis of hypertension: Focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. Journal of Clinical Hypertension (Greenwich), 14(4), 198–205. https://doi.org/10.1111/j.1751-7176.2012.00606CrossRef

68.

Rahman, M. S. (2019). Prostacyclin: A major prostaglandin in the regulation of adipose tissue development. Journal of Cellular Physiology, 234(4), 3254–3262. https://doi.org/10.1002/jcp.26932CrossRefPubMed

69.

Oh, R. C., Hustead, T. R., Ali, S. M., & Pantsari, M. W. (2017). Mildly elevated liver transaminase levels: Causes and evaluation. American Family Physician, 96(11), 709–715.PubMed

70.

Morisco, F., Pagliaro, L., Caporaso, N., Bianco, E., Sagliocca, L., Fargion, S., Smedile, A., Salvagnini, M., & Mele, A. (2008). Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: Suggestions for diagnostic procedures and monitoring. Digestive Liver Diseases, 40(7), 585–598. https://doi.org/10.1016/j.dld.2008.02.003CrossRef

71.

Yu, K. J., Zhang, M. J., Li, Y., & Wang, R. T. (2014). Increased whole blood viscosity associated with arterial stiffness in patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 29(3), 540–544. https://doi.org/10.1111/jgh.12368CrossRefPubMed

72.

Trak-Smayra, V., Dargere, D., Noun, R., Albuquerque, M., Yaghi, C., Gannagé-Yared, M. H., Bedossa, P., & Paradis, V. (2009). Serum proteomic profiling of obese patients: Correlation with liver pathology and evolution after bariatric surgery. Gut, 58(6), 825–832. https://doi.org/10.1136/gut.2007.140087CrossRefPubMed

73.

Chen, S., Guo, X., Zhang, X., Yu, S., Yang, H., Jiang, M., Sun, G., & Sun, Y. (2015). Association between elevated serum alanine aminotransferase and cardiometabolic risk factors in rural Chinese population: A cross-sectional study. BMC Cardiovascular Disorders, 15, 65. https://doi.org/10.1186/s12872-015-0060-yCrossRefPubMedPubMedCentral

74.

Cao, Y., Pan, Q., Cai, W., Shen, F., Chen, G. Y., Xu, L. M., & Fan, J. G. (2016). Modulation of gut microbiota by berberine improves steatohepatitis in high-fat diet-fed BALB/C mice. Archives of Iranian Medicine, 19, 197–203.PubMed

75.

Shen, F., Zheng, R. D., Sun, X. Q., Ding, W. J., Wang, X. Y., & Fan, J. G. (2017). Gut microbiota dysbiosis in patients with nonalcoholic fatty liver disease. Hepatobiliary and Pancreatic Diseases International, 16, 375–381. https://doi.org/10.1016/S1499-3872(17)60019-5CrossRefPubMed

76.

Zhou, D., & Fan, J. G. (2019). Microbial metabolites in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 25(17), 2019–2028. https://doi.org/10.3748/wjg.v25.i17.2019CrossRefPubMedPubMedCentral

77.

Engstler, A. J., Aumiller, T., Degen, C., Dürr, M., Weiss, E., Maier, I. B., Schattenberg, J. M., Jin, C. J., Sellmann, C., Bergheim, I., et al. (2016). Insulin resistance alters hepatic ethanol metabolism: Studies in mice and children with non-alcoholic fatty liver disease. Gut, 65, 1564–1571. https://doi.org/10.1136/gutjnl-2014-308379CrossRefPubMed

78.

Brewster, L. M., Mairuhu, G., Bindraban, N. R., Koopmans, R. P., Clark, J. F., & van Montfrans, G. A. (2006). Creatine kinase activity is associated with blood pressure. Circulation, 114(19), 2034–2039. https://doi.org/10.1161/CIRCULATIONAHA.105.584490CrossRefPubMed

79.

Brewster, L. M., Karamat, F. A., & van Montfrans, G. A. (2019). Creatine kinase and blood pressure: A systematic review. Medical Sciences (Basel), 7(4), 58. https://doi.org/10.3390/medsci7040058CrossRef

80.

Watanabe, M., Okamura, T., Kokubo, Y., Higashiyama, A., & Okayama, A. (2009). Elevated serum creatine kinase predicts first-ever myocardial infarction: A 12-year population-based cohort study in Japan, the Suita study. International Journal of Epidemiology, 38(6), 1571–1579. https://doi.org/10.1093/ije/dyp212CrossRefPubMed

81.

Matschinsky, F. M., & Wilson, D. F. (2019). The central role of glucokinase in glucose homeostasis: A perspective 50 years after demonstrating the presence of the enzyme in islets of langerhans. Frontier in Physiology, 10, 148. https://doi.org/10.3389/fphys.2019.00148CrossRef

82.

Matschinsky, F. M. (2013). GKAs for diabetes therapy: Why no clinically useful drug after two decades of trying? Trends in Pharmacological Sciences, 34, 90–99. https://doi.org/10.1016/j.tips.2012.11.007CrossRefPubMed

83.

Arriarán, S., Agnelli, S., Sabater, D., Remesar, X., Fernández-López, J. A., & Alemany, M. (2015). Evidences of basal lactate production in the main white adipose tissue sites of rats. Effects of sex and a cafeteria diet. PLoS ONE, 10(3), e0119572. https://doi.org/10.1371/journal.pone.0119572CrossRefPubMedPubMedCentral

84.

Moon, C. M., Oh, C. H., Ahn, K. Y., Yang, J. S., Kim, J. Y., Shin, S. S., Lim, H. S., Heo, S. H., Seon, H. J., Kim, J. W., & Jeong, G. W. (2017). Metabolic biomarkers for non-alcoholic fatty liver disease induced by high-fat diet: In vivo magnetic resonance spectroscopy of hyperpolarized [1-13C] pyruvate. Biochemical Biophysical Research Communications, 482(1), 112–119. https://doi.org/10.1016/j.bbrc.2016.08.118CrossRefPubMed

85.

Andersen, T., Christoffersen, P., & Gluud, C. (1984). The liver in consecutive patients with morbid obesity: A clinical, morphological, and biochemical study. International Journal of Obesity, 8(2), 107–115.PubMed

86.

Choi, J. W. (2003). Association between elevated serum hepatic enzyme activity and total body fat in obese humans. Annals of Clinical Laboratory Sciences, 33(3), 257–264.

87.

Jeon, J., Morris, J. S., & Park, K. (2021). Toenail mercury levels positively correlate with obesity and abdominal obesity among Korean adults. Journal of Trace Elements in Medicine and Biology, 64, 126678. https://doi.org/10.1016/j.jtemb.2020.126678CrossRefPubMed

88.

Wang, X., Mukherjee, B., & Park, S. K. (2018). Associations of cumulative exposure to heavy metal mixtures with obesity and its comorbidities among U.S. adults in NHANES 2003–2014. Environment International, 121(Pt 1), 683–694. https://doi.org/10.1016/j.envint.2018.09.035CrossRefPubMedPubMedCentral

89.

Cho, H. W., Kim, S. H., & Park, M. J. (2020). An association of blood mercury levels and hypercholesterolemia among Korean adolescents. Sciences of Total Environment, 709, 135965. https://doi.org/10.1016/j.scitotenv.2019.135965CrossRef

90.

Lee, S., Cho, S. R., Jeong, I., Park, J. B., Shin, M. Y., Kim, S., & Kim, J. H. (2020). Mercury exposure and associations with hyperlipidemia and elevated liver enzymes: A nationwide cross-sectional survey. Toxics, 8(3), 47. https://doi.org/10.3390/toxics8030047CrossRefPubMedCentral

91.

Emery, M. G., Fisher, J. M., Chien, J. Y., Kharasch, E. D., Dellinger, E. P., Kowdley, K. V., & Thummel, K. E. (2003). CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology, 38(2), 428–435. https://doi.org/10.1053/jhep.2003.50342CrossRefPubMed

92.

Chiu, K., Warner, G., Nowak, R. A., Flaws, J. A., & Mei, W. (2020). The impact of environmental chemicals on the gut microbiome. Toxicological Sciences, 176(2), 253–284. https://doi.org/10.1093/toxsci/kfaa065CrossRefPubMedPubMedCentral

93.

Claus, S., Guillou, H., & Ellero-Simatos, S. (2016). The gut microbiota: A major player in the toxicity of environmental pollutants? Biofilms and Microbiomes, 2, 16003. https://doi.org/10.1038/npjbiofilms.2016.3CrossRefPubMedPubMedCentral

94.

Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., Zhao, X., Li, N., Li, S., Xue, G., Cheng, W., Li, B., Li, H., Lin, W., Tian, C., Zhao, J., Han, J., An, D., Zhang, Q., … Liu, D. (2019). Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae. Cell Metabolism, 30(4), 675-688.e7. https://doi.org/10.1016/j.cmet.2019.08.018CrossRefPubMed

Title: Interplay of Obesity, Ethanol, and Contaminant Mixture on Clinical Profiles of Cardiovascular and Metabolic Diseases: Evidence from an Animal Study
Authors: Maria Florian
Bai Li
Dominique Patry
Jocelyn Truong
Don Caldwell
Melanie C. Coughlan
Robert Woodworth
Jin Yan
Qixuan Chen
Ivan Petrov
Laziyan Mahemuti
Michelle Lalande
Nanqin Li
Laurie H. M. Chan
William G. Willmore
Xiaolei Jin
Publication date: 01-06-2022
Publisher: Springer US
Keywords: Obesity
Obesity
Published in: Cardiovascular Toxicology / Issue 6/2022
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-022-09738-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interplay of Obesity, Ethanol, and Contaminant Mixture on Clinical Profiles of Cardiovascular and Metabolic Diseases: Evidence from an Animal Study

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2022

Correlation Between Glycated Hemoglobin (HbA1c) and Post-Systolic Index Measured by Speckle-Tracking Echocardiography in Patients with Non-apparent Coronary Artery Disease

NPAS4 Polymorphisms Contribute to Coronary Heart Disease (CHD) Risk

Exosomes Derived from Mesenchymal Stem Cells Ameliorate the Progression of Atherosclerosis in ApoE−/− Mice via FENDRR

Protective Effects of Sauropus Androgynus Leaf Extract against Isoproterenol Induced Cardiotoxicity

Exercise Training Attenuates Cardiac Vulnerability and Promotes Cardiac Resistance to Isoproterenol-Induced Injury Following Hookah Smoke Inhalation in Male Rats: Role of Klotho and Sirtuins

Exosomes Derived from Senescent Endothelial Cells Contain Distinct Pro-angiogenic miRNAs and Proteins

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page